Csenge Advisory Group Buys 71 Shares of Zoetis Inc. (NYSE:ZTS)

Csenge Advisory Group lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,700 shares of the company’s stock after acquiring an additional 71 shares during the quarter. Csenge Advisory Group’s holdings in Zoetis were worth $988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC boosted its position in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares in the last quarter. Webster Bank N. A. boosted its holdings in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares in the last quarter. Private Wealth Management Group LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $33,000. Gladius Capital Management LP bought a new stake in shares of Zoetis in the 4th quarter valued at $40,000. Finally, Neo Ivy Capital Management acquired a new position in shares of Zoetis during the 4th quarter valued at $40,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ZTS shares. Stifel Nicolaus raised their price target on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Monday. HSBC dropped their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Barclays cut their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, The Goldman Sachs Group reduced their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $214.89.

Zoetis Stock Up 1.9 %

ZTS stock opened at $188.30 on Friday. The stock’s 50 day moving average is $176.47 and its 200-day moving average is $175.51. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The firm has a market capitalization of $85.92 billion, a PE ratio of 36.28, a P/E/G ratio of 2.85 and a beta of 0.86. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.47% and a net margin of 26.29%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business earned $1.41 EPS. Sell-side analysts expect that Zoetis Inc. will post 5.81 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a yield of 0.92%. Zoetis’s dividend payout ratio (DPR) is 33.14%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.